An ELISA method to compute endpoint titers to Epstein–Barr virus and cytomegalovirus: Application to population-based studies

Raymond P. Stowe a,⁎, R. Jeanne Ruiz b, Christopher P. Fagundes c, Robin H. Stowe a, Min Chen d,e, Ronald Glaser d,e

a Microgen Laboratories, La Marque, TX, United States
b Gayle Greve Hunt College of Nursing, Texas Tech University Health Sciences Center, El Paso, TX, United States
c Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, United States
d Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH, United States
e Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, United States

ARTICLE INFO

Article history:
Received 28 January 2014
Received in revised form 7 May 2014
Accepted 13 May 2014
Available online 22 May 2014

Keywords:
Herpesvirus
EBV
CMV
ELISA
Antibody titer
IFA

ABSTRACT

Indirect fluorescence analysis (IFA), the gold standard for determining herpesvirus antibody titers, is labor-intensive and poorly suited for large population-based studies. The enzyme-linked immunosorbent assay (ELISA) is used widely for measuring antiviral antibodies but also suffers drawbacks such as reduced specificity and the qualitative nature of the results due to limited interpretation of the optical density (OD) units. This paper describes a method to titer herpesvirus antibodies using microplates coated with virally-infected cells in which a standard curve, derived from IFA-scored samples, allowed OD units to be converted into titers. A LOOKUP function was created in order to report the data as traditional IFA-based (i.e., 2-fold) titers. The modified ELISA correlated significantly with IFA and was subsequently used to compute endpoint antibody titers to Epstein–Barr virus (EBV)-virus capsid antigen (VCA) and cytomegalovirus (CMV) in blood samples taken from 398 pregnant Hispanic women. Four women were EBV negative (1%), while 58 women were CMV negative (14.6%). EBV VCA antibody titers were significantly higher than CMV antibody titers (p < 0.001). This method allows titering of herpesvirus antibodies by ELISA suitable for large population-based studies. In addition, the LOOKUP table enables conversion from OD-derived titers into 2-fold titers for comparison of results with other studies.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Herpesviruses commonly establish latent infections in the majority of adults worldwide. The best known members of this family include cytomegalovirus (CMV) and Epstein–Barr virus (EBV). Herpesviruses are medically important viruses; EBV infects over 90% of the adult population and is the causative agent of infectious mononucleosis, Burkitt’s lymphoma, nasopharyngeal carcinoma, and diffuse polyclonal B-cell lymphoma. As with EBV, infection with CMV usually occurs asymptptomatically during childhood but may result in a mononucleosis-like syndrome, central nervous system infections, and febrile illnesses. Notably, EBV and CMV infections can be severe in immunocompromised individuals such as AIDS and post transplant patients.

While the medical importance and effects of symptomatic herpesvirus infections are well documented, recent attention has focused on the effects of life-long infection and subclinical reactivation of these viruses. Studies have found an association between herpesvirus seropositivity and inflammation, kidney

http://dx.doi.org/10.1016/j.jim.2014.05.006
0022-1759/© 2014 Elsevier B.V. All rights reserved.
immune function and high antiviral antibody titers (Gray et al., 2001, 2005; Wall et al., 2013). CMV in particular has been associated with an immune risk phenotype, cardiovascular disease, and higher mortality (Wikby et al., 2006; Simanek et al., 2011).

Maladaptive alterations in cellular immune function can enhance latent herpesvirus reactivation and replication, resulting in elevated antibody titers. Elevated herpesvirus antibodies have been linked to a number of diseases. As an example, organ transplant patients provide a dramatic illustration of the association between dysregulated cellular immune function and high antiviral antibody titers (Gray et al., 1995). High levels of herpesvirus antibodies have also been linked to premature mortality (Aiello et al., 2006, 2008), development of coronary artery disease (Kendall et al., 1992), fatigue before cancer treatment (Fagundes et al., 2012), and cognitive impairment in elderly adults with cardiovascular disease (Strandberg et al., 2003). In addition, elevated CMV antibodies were associated with cognitive impairment even after controlling for numerous covariates including age, education, and health conditions (Aiello et al., 2006).

The gold standard for measuring antiviral antibodies is the indirect fluorescence analysis (IFA) method. In general, a blood serum or plasma sample containing antibody is serially diluted (e.g., 1:10, 1:20, 1:40, 1:80). The dilutions are then applied to slide wells containing both virally-infected cells and uninfected cells (built-in control to distinguish non-specific reactions). Following a short incubation time, an appropriate fluorescent antibody (IgG or IgM) conjugate with counterstain is added to each of the slide wells. The slides are then read manually on a fluorescent microscope with appropriate filters. The assigned titer is indicative of the last dilution in which the antibody was detected. For example, if antibody was detected in each of the tubes listed above except for the 1:80 dilution, the titer is said to be 40. Therefore the titer is the degree to which the antibody–serum solution can be diluted and still contain detectable amounts of antibody.

Although highly specific, IFA is labor-intensive and not suitable for large numbers of samples. For instance, measurement of antibody titers to three herpesviruses by IFA in samples from 1457 subjects (Stowe et al., 2010) required 4–5 months. In addition, results can vary between laboratories due to differences in type or condition of fluorescence microscope employed as well as the experience level of personnel performing the assay. Accordingly, the enzyme-linked immunosorbent assay (ELISA) has become a widespread method of screening for antiviral antibodies in population-based studies. If the viral antibody is present in the patient sample, the antibody will bind to the antigen on the plates. Upon addition of an enzyme-linked secondary antibody, a color-generating reaction occurs that increases the optical density (OD). The results are reported as positive if the observed OD for a patient sample is above the specified threshold for the assay or negative if the OD is below the threshold. However, this method also has several drawbacks including: 1) synthetic peptides as antigens are less sensitive and less specific; 2) the number and quantity of antigens have not been standardized resulting in manufacturer-to-manufacturer test variability, and 3) the results are qualitative (i.e., negative/positive) or semi-quantitative due to the limited interpretation of the OD units (Hess, 2004).

This paper describes a new method to titer EBV and CMV antibodies for use in population-based studies. Microplates coated with the same virally-infected cells used for IFA substrate slides were used as the source of antigen. IFA-scored plasma samples were then used to create a standard curve allowing OD units to be converted into titers. To report the results as 2-fold titers, a LOOKUP function was created to transform the OD-derived values. The results show that this approach constitutes a rapid, quantitative method to titer EBV and CMV antibodies in large scale studies.

2. Materials and methods

2.1. Samples

Plasma samples from 398 pregnant Hispanic women (ages 14–45; mean age 25 ± 6) were used for this study (Ruiz et al., 2012). In addition, plasma was obtained from peripheral blood samples taken from 32 healthy adults (20 males and 12 non-pregnant females, mean age = 29) as a comparison group. The Institutional Review Board at the University of Texas Austin approved the study, and all participants gave informed consent.

2.2. Measurement of anti-viral antibodies by IFA

Anti-viral antibody titers were determined by indirect immunofluorescence as previously described (Stowe et al., 2001, 2007, 2010). Commercially prepared substrate slides and control sera (Bion Enterprises, Park Ridge, IL) were used for determining IgG antibody titers to EBV-viral capsid antigen (VCA) and CMV. Briefly, 30 μl of serially diluted plasma was pipetted onto spot slides and incubated for 30 min at room temperature. For VCA, the antigen substrate slides contained a mixture of EBV (P3HR1 strain) infected and uninfected lymphocytic cells fixed onto each well. For CMV, the antigen substrate slides contained a mixture of CMV (clinical specimen) infected and uninfected human diploid fibroblast cells fixed onto each well. Each well contained an average of 10–20% infected cells per 200× field. After incubation, the spot slides were rinsed for 5 min in PBS. The secondary antibody used was anti-human IgG conjugated with fluorescein isothiocyanate (FITC). Evans blue was used as a counterstain. After a second incubation (30 min at room temperature), slides were washed, lightly blotted, and mounted with a mounting medium. All specimens were batch-analyzed and read blind-coded. Slides were read using an Axioskop microscope (Zeiss, Oberkochen, Germany) with appropriate barrier and excitation filters for FITC visualization. The endpoint titer was determined as the highest dilution of serum demonstrating immunofluorescent-positive cells.

2.3. ELISA-based method for titer determination

Ninety-six well microtiter plates, coated with virally infected cells, were obtained from Euroimmun (Morris Plains, NJ). Antigen source for VCA plates (EL 2791-9601-G) was inactivated cell lysates of lymphocytes infected with the P3HR1 strain of EBV. The antigen sources for the CMV plates (EL 2570-9601-G) were inactivated cell lysates of MRC-5 (diploid fibroblast) cells infected with the CMV AD169 strain. These kits include cut-off calibrators to differentiate samples from individuals with prior exposure (i.e., seropositive).
Plasma samples with high IFA-scored antibody titers (i.e., 2560), obtained from prior studies, were used as the top standards for both VCA and CMV. Seven two-fold serial dilutions of the top standards were made with PBS in separate tubes. After diluting, the VCA and CMV standards were 2560, 1280, 640, 320, 160, 80, 40, and 20. One hundred microliters of positive and negative controls, standards, and diluted patient samples (all dilutions were at 1:101 with PBS) was pipetted in duplicate into individual microplate wells followed by a 30 min incubation (all steps were carried out at room temperature). The plates were then washed 3 times with 350 μl wash buffer (provided) using an Embla microplate washer (Molecular Devices, Menlo Park, CA). Next, 100 μl of enzyme conjugate (peroxidase labeled anti-human IgG) was pipetted into the wells followed by another 30 min incubation period. The plates were then washed 3 times, and 100 μl of chromogen substrate (TMB/H2O2) was pipetted into the wells. The plates were then covered to protect from direct light and incubated for 15 min. One hundred microliters of 0.5 M sulphuric acid) was added to each well to stop the reaction. Absorbance was then read at 450 nm (reference wavelength 620 nm) using a SpectraMax Plus 384 (Molecular Devices). The values of the unknown samples were assigned in relation to the standard curve.

2.4. Excel look up function

A LOOKUP function was created in order to transform OD-derived titers into 2-fold titers (as would be obtained with IFA). The LOOKUP function returns a value either from a one-row or one-column range or from an array. A data table was written that returns a specific titer depending on the titer range (Fig. 1). For instance, a titer of 80 was assigned for OD-derived titers that ranged from 60 to 119; a titer of 160 was assigned for OD-derived titers that ranged from 120 to 239. The syntax was as follows: LOOKUP (lookup_value, lookup_vector, result_vector). The function was then copied onto cells adjacent to the data column containing the OD-derived titer values for subsequent transformation.

2.5. Statistical analysis

Statistical analysis was performed using SigmaStat software v2.03 (SPSS, Chicago, IL). Normality was assessed using the Kolmogorov–Smirnov normality test. Data not normally distributed were subjected to natural log transformations to normalize the distributions prior to analyses. Since the method of doubling dilutions was used to obtained antibody titer results, a log base-2 transformation was used to reduce variance for statistical comparisons. Where expressed, results are mean ± SE and p values less than 0.05 were considered significant.

3. Results

3.1. Validation of the ELISA method for antiviral antibody titers

Typical analyses of VCA standards are shown in Table 1. The highest standard (St01) yielded a mean OD value of 2.245 and a standard deviation of 0.023 (CV = 1.0%). Serial dilutions yielded results with excellent standard deviations (range 0.002–0.021) and CVs (range 0.1–3.0). Similar results were found for CMV (Table 2). The highest standard (St01) yielded a mean OD value of 2.248 and a standard deviation of 0.071 (CV = 3.2%). Serial dilutions also yielded results with excellent standard deviations (range 0.000–0.071) and CVs (range 0.0–3.2). Initial analyses showed that the data points for the VCA and CMV standards were not linear (data not shown). However, using a non-linear regression curve (a 4-parameter logistic curve fit commonly used for immunoassays) gave excellent results (Fig. 2; VCA). Data for CMV also showed an excellent correlation (r² = 0.999; data not shown).

![Fig. 1. LOOKUP table for assigning titers (2-fold) from ELISA-derived titer data. The sample numbers are indicated in column A. Columns B and C show the (raw) OD and titer (calculated from the standard curve) data, respectively. The titer values are then compared against the table data (contained in columns F2:G14) for conversion into an IFA-assigned titer (column D).](image-url)
The assay precision, defined using three different samples, has been reported by the manufacturer: CVs within and between assays were 4.2–7.4% (n = 20) and 3.2–8.2% (n = 20), respectively. The intra-assay variation of the VCA and CMV plates was tested by running 16 replicates on the same plate. The mean OD and standard error were 2.0 ± 0.03 for VCA (CV = 5.6%) and 1.6 ± 0.03 for CMV (CV = 8.3%); these results are in line with data from the manufacturer test runs. The VCA and CMV assays are reported by the kit manufacturer not to be cross-reactive with other herpesviruses, measles, mumps, and rubella. In the current study cross-reactivity between herpesviruses, including herpes simplex virus type 1 (HSV-1), was not found after testing these samples which is in agreement with the manufacturer’s results (data not shown).

Table 1
Analysis of EBV VCA standards.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Concentration</th>
<th>Value range</th>
<th>Mean value</th>
<th>Std. dev.</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>St01</td>
<td>2560.00</td>
<td>2.229–2.262</td>
<td>2.245</td>
<td>0.023</td>
<td>1.0</td>
</tr>
<tr>
<td>St02</td>
<td>1280.00</td>
<td>1.953–1.956</td>
<td>1.954</td>
<td>0.002</td>
<td>0.1</td>
</tr>
<tr>
<td>St03</td>
<td>640.00</td>
<td>1.569–1.582</td>
<td>1.576</td>
<td>0.0009</td>
<td>0.6</td>
</tr>
<tr>
<td>St04</td>
<td>320.00</td>
<td>1.145–1.146</td>
<td>1.145</td>
<td>0.001</td>
<td>0.1</td>
</tr>
<tr>
<td>St05</td>
<td>160.00</td>
<td>0.748–0.778</td>
<td>0.763</td>
<td>0.021</td>
<td>2.8</td>
</tr>
<tr>
<td>St06</td>
<td>80.00</td>
<td>0.451–0.457</td>
<td>0.454</td>
<td>0.005</td>
<td>1.0</td>
</tr>
<tr>
<td>St07</td>
<td>40.00</td>
<td>0.261–0.272</td>
<td>0.267</td>
<td>0.008</td>
<td>3.0</td>
</tr>
<tr>
<td>St08</td>
<td>20.00</td>
<td>0.156–0.159</td>
<td>0.158</td>
<td>0.002</td>
<td>1.6</td>
</tr>
</tbody>
</table>

The mean VCA antibody titer was significantly higher than the mean CMV antibody titer (8.0 vs. 7.3; p < 0.001). In comparison, none of the samples from the 32 healthy adults were EBV negative while four were CMV negative. The mean VCA antibody titer was significantly higher than the mean CMV antibody titer (7.6 vs. 5.6; p < 0.001). When comparing between groups, there were no significant differences in VCA IgG antibody titers. However, the mean CMV antibody titer for the group of pregnant females was significantly higher than that of the adult subject group (p < 0.002).

The OD-derived titers were then transformed using the LOOKUP table. EBV VCA titers ≥320 are considered elevated and are correlated with reactivation in immunosuppressed individuals (Horwitz et al., 1985; Jenson, 2011). Other investigators, using EBV VCA titers ≥640 as a cutoff, found an increased risk of disease progression (Schetter et al., 2008). Therefore, the EBV and CMV data was further analyzed by using both cutoffs (i.e., ≥320 and ≥640).

When comparing EBV and CMV titers within groups, both groups had a significantly greater number of subjects with elevated VCA titers (≥320 and ≥640) than with elevated CMV titers (p < 0.01; chi-square test). There were no significant differences in VCA or CMV antibody titers between the two groups. Further analysis of the pregnant female group showed that 8 of the 336 co-infected subjects (2%) had IgG antibody titers ≥640 for both VCA and CMV, while 23 subjects (7%) had VCA antibody titers ≥640 and CMV antibody titers ≥320 (data not shown). There were no significant differences in EBV antibody titers between the CMV-negative and -positive pregnant Hispanic women. However, VCA antibody titers were significantly greater in pregnant Hispanic women with treatment-related disease progression.
high CMV IgG titers (≥320) as compared to those with less than 320 (p < 0.05).

4. Discussion

In the current study the utility of a new ELISA-based method to rapidly titer (<2 h) CMV and EBV antibodies was demonstrated with a large number of samples. Using IFA-scored plasma samples to create a standard curve similar to cytokine ELISA assays, an OD reading was able to be converted into a meaningful unit of measure (i.e., a titer). For instance, a titer is required to determine if viral reactivation has occurred by observing a 4-fold or greater increase between paired blood samples; elevated antibodies may also indicate reactivation (Stowe et al., 2000, 2010). A high positive correlation was found between the IFA and ELISA methods, partly due to the use of the same substrate (i.e., virally-infected cells), which validated the approach (i.e., IFA-scored sample for use as standards) has been used to titer antibodies to EBV early antigen (EA), HSV-1, EBV VCA (5.5–12.3), CMV (5.6–10.4), EBV VCA ≥640 (210) and EBV VCA ≥320 (7.3 ± 0.05) titers for comparison of results with other studies.

Multiple plasma samples pre-titered at 2560 by IFA were required to determine if viral reactivation has occurred by observing a 4-fold or greater increase between paired blood samples; elevated antibodies may also indicate reactivation (Stowe et al., 2000, 2010). A high positive correlation was found between the IFA and ELISA methods, partly due to the use of the same substrate (i.e., virally-infected cells), which validated the approach (i.e., IFA-scored sample for use as standards) has been used to titer antibodies to EBV early antigen (EA), HSV-1, EBV VCA (5.5–12.3), CMV (5.6–10.4), EBV VCA ≥640 (210) and EBV VCA ≥320 (7.3 ± 0.05) titers for comparison of results with other studies.

High accuracy in measuring antibody titers along with serostatus to herpesviruses in a group of pregnant Hispanic females and a group of healthy adults. Brain Behav. Immun. 26, 739.

This assay was used to measure EBV and CMV antibody titers in pregnant Hispanic women. In agreement with prior studies of Hispanics (Stowe et al., 2010), the majority of these individuals were found to be infected with multiple herpesviruses. In addition, EBV antibodies were significantly higher than CMV antibodies. Notably, subjects with elevated CMV antibodies had significantly higher EBV antibodies than those with lower CMV antibodies. Notably, this type of relationship has been associated with an inflammatory state in older adults (Bennett et al., 2011) and is consistent with previous literature linking total pathogen burden and inflammation (Zhu et al., 2000; Nazmi et al., 2010; Roberts et al., 2010).

CMV antibodies were significantly greater in pregnant Hispanic females as compared to the healthy adult group. Notably, impaired cellular immunity results in higher antiviral IgG antibodies reflecting viral reactivation (Glaser et al., 1991, 1994; Stowe et al., 2000; Glaser and Kiecolt-Glaser, 2005). It is possible that the results from the current study may reflect downregulation of cell-mediated immunity, perhaps due in part to the Th2-type immunity associated with pregnancy (Wegmann et al., 1993; Piccinni et al., 1998). Future studies are needed to examine the role of herpesviruses in pregnancy and preterm birth.

Overall these results demonstrate a new approach to measuring antiviral antibodies. Previous studies (e.g., NHANES) used standard ELISA approaches for determining EBV and CMV serostatus which limited interpretation of the viral data. For instance, viral data in NHANES III for subjects over age 49 were top-coded making them unusable as a predictor of mortality (Dowd and Aiello, 2009; Simanek et al., 2011). In addition, OD values alone make it impossible to correlate antibody levels as an indicator of reactivation. Although some of these studies used upper quartiles to define high antibody levels, using an arbitrary cutoff can skew the data interpretation depending on the size of the sample. For instance, further analysis of the current data showed that the upper quartile was not a significant predictor of infant physical characteristics. However, when using a defined titer cutoff similar to prior work (Stowe et al., 2010), it was found that elevated titers predicted specific infant physical characteristics. Future studies should include measurement of antibody titers along with serostatus to examine the role of herpesvirus reactivation in poor health outcomes.

Acknowledgments

This work was supported by the National Institute of Allergy and Infectious Diseases (R03AI081021, R03AI083062, and R01AI084898), the National Institute of Nursing Research (R01NR007891), and the National Space and Aeronautics Administration (NNJ06HB73A).

References


This work was supported by the National Institute of Allergy and Infectious Diseases (R03AI081021, R03AI083062, and R01AI084898), the National Institute of Nursing Research (R01NR007891), and the National Space and Aeronautics Administration (NNJ06HB73A).

References


